Perrigo Announces FDA Final Approval For Generic Equivalent To Cutivate Lotion
ALLEGAN (WWJ) — Perrigo Co. (NYSE: PRGO) Wednesday announced that it has received final approval for its abbreviated new drug application for fluticasone propionate lotion, 0.05%, the generic equivalent to Cutivate Lotion, 0.05%.
Perrigo will commence shipment of the product immediately.
Cutivate Lotion 0.05% (fluticasone propionate lotion, 0.05%) is indicated for the relief of the inflammatory and pruritic manifestations of atopic dermatitis — in common terms, skin rash — in patients 1 year of age or older and has annual sales of approximately $19 million, as measured by Symphony Health Solutions.
“This is another example of our prescription team’s commitment to launching difficult to manufacture topicals, lotions and foams,” said Perrigo chairman and CEO Joseph C. Papa. “We are excited to market this product and are dedicated to making quality healthcare more affordable for all consumers around the globe.”
Perrigo was founded as a packager of generic home remedies in 1887. It is now the world’s largest manufacturer of over-the-counter pharmaceutical products for the store brand market. Perrigo Company also makes and generic prescription pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements and active pharmaceutical ingredients. Perrigo’s primary markets are , Mexico, the United Kingdom, India, China and Australia.
More at http://www.perrigo.com.